Israeli company Galmed Pharmaceuticals Ltd., which is developing proprietary drugs for the treatment of fatty liver disease, is planning a multi-million IPO at a company value of $100 million. “Globes” reports that the decision will be made by October, and if the decision is taken to go ahead, the IPO will be held in December.
Related posts
Israeli AI Safety Tool Among TIME’S Best Inventions For 2024
October 31, 2024
TAU Team Discovers Mechanism To Eliminate Cancerous Tumors
October 30, 2024
Ashdod Port Investing In Startups As Part Of Innovation Strategy
October 29, 2024
BGU Develops Fast Fact Checking Via News Sources Not People
October 28, 2024
Facebook comments